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OBJECTIVE: To estimate the prevalence of female sexual dysfunction symptoms and the associated risk factors in
a sample of patients with substance-related disorders admitted to a specialized in-patient care unit.
METHODS: This study used a cross-section design, with eight months of data collection, conducted with
substance-dependent women using structured questionnaires to collect socio-demographic data and identify
their drug of choice. The Drug Abuse Screening Test, Short Alcohol Dependence Data questionnaire,
Fagerstro¨m Test for Nicotine Dependence, and Arizona Sexual Experience Scale were also administered.
RESULTS: The sample consisted of 105 women who had a mean age of 34.8 years (SD=12.1, range=18-65) and
were predominantly heterosexual (74.3%), single (47.6%), Caucasian (50.5%), catholic (36.2%), and educated
only to the level of primary education (40%), with a monthly family income of up to one minimum salary
(37.5%). In 42.9% of the patients, crack was the drug of choice; 47.6% of the sample qualified for the Drug
Abuse Screening Test (substantial problems related to drugs), 43.8% exhibited Short Alcohol Dependence Data
(moderate or severe dependency), 47.6% exhibited Fagerstro¨m Test for Nicotine Dependence (high or very high
nicotine dependence). The prevalence of sexual dysfunction symptoms was 34.2% (95% CI = [25.3, 44.1]), and a
high level of nicotine dependence and low income increased the chances of having sexual dysfunction by 2.72-
fold and 2.54 fold, respectively. An association was also observed between female sexual dysfunction symptoms
and schooling and levels of drug dependence.
CONCLUSIONS: Female sexual dysfunction symptoms were common among this sample and primarily associated
with high levels of nicotine use.
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& INTRODUCTION
Female sexual dysfunction (FSD) is a common disorder in
societies worldwide, but it is also a complex multifactor
phenomenon that encompasses emotional intimacy and
relationship satisfaction, along with other psychosocial
factors across all cultures, all sexual orientations and
various socio-economic statuses, with a great potential to
affect relationships negatively and impair quality of life
(1-3).
Epidemiological studies in the United States have
estimated that FSD affected 43% of women in the general
population over the past 12 months (4). In the United
Kingdom, 5.8% of women have reported recent sexual
dysfunction, and 15.5% have reported lifelong sexual
dysfunction (1), whereas in Latin America, the rate of FSD
for middle aged women it is approximately 58% (5). Some
studies on this issue have indicated that among women with
any sexual difficulty, an average of 64% (range = 16-75%)
experienced difficulty with desire, 35% (range = 16-48%)
experienced difficulty achieving orgasm, 31% (range = 12-
64%) experienced difficulty becoming aroused, and 26%
(range = 7-58%) experienced sexual pain (1,4,6).
Unfortunately, this condition remains a largely under-
explored field in medicine, despite (a) sexual dysfunction
being more prevalent in women than in men and (b) the
evolution of nonlinear models due to understanding the
intricacy of female sexual function that recognize the
importance of both nonbiological and biological factors
(1,7-9).
Some of the psychological factors associated with FSD
include the unconscious avoidance of sex and pleasure, fear,
structured rigid families, the demands of a relationship, and
an excessive need to satisfy the partner. In addition, the
guilt that comes from experiencing pleasure can be
internalized as a potential risk and danger, which in turn
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leads to both insecurity and a repression of the body and
possible pleasure that it can experience (4,7).
Alcohol consumption, tobacco smoking, and illicit drug
abuse/dependence have long been associated with sexual
dysfunction (10-12). Among chronic heroin and morphine
users, for example, a review study noted decreases in sexual
intercourse frequency, masturbation, and the quality and
frequency of orgasm (13). These effects occur because
opioids inhibit the hypothalamic-pituitary-gonadal axis
and increase prolactin levels, which affect both the male
and female sexual response (13).
Animal and in vitro studies examining the effects of
cannabis abuse on sexual function have identified potential
links between chronic cannabis smoking and inhibited
orgasms (13-15). Chronic cocaine abuse is also associated
with hyperprolactinemia and sexual dysfunction symptoms,
such as diminished libido and difficulty reaching orgasm
(11,12).
In alcohol-dependent women, the most common forms of
sexual dysfunction observed include dyspareunia, high
rates of genitourinary health problems, and low vaginal
lubrication, revealing problems with sexual arousal (13,16).
Other factors that may predict symptoms of sexual
dysfunction in this population include a history of sexual
abuse, psychiatric comorbidities (such as depression,
anxiety, and eating disorders) that commonly co-occur with
dependence to alcohol and other drugs in women, various
specific symptoms associated with the abuse of psychoac-
tive substances (such as "crashing" after cocaine use), and
insomnia problems (3,10,16).
Furthermore, research on the relationship between FSD
symptoms and drug abuse (especially for other drugs, such
as crack) has been neglected to an even greater extent
(11,13). Nevertheless, identifying the magnitude of this
problem and managing the sexual health issues among this
population may have a significant impact on the prevention
of relapse. Managing this problem is especially important
because the use of psychoactive substances may be involved
in the relief of symptoms related to sexual dysfunction or
result from a search for ‘‘anesthesia feelings’’ in response to
the frustration of not achieving sexual pleasure (17).
The scarcity of data on the prevalence of sexual dysfunc-
tion symptoms in women, especially among crack users,
justifies the expansion of scientific evidence in this area
(6,13). Our hypothesis is that FSD occurs more frequently in
addict patients than the general population and is largely
associated with alcohol, crack, and polydrug abuse.
The objective of this study was to evaluate the prevalence
of sexual dysfunction and the associated risk factors among
a sample of substance-dependent women admitted to an
inpatient care service.
& METHODS
This study was approved by the Federal University of Sa˜o
Paulo Ethics Committees (protocol number 1193/09), and
all of the subjects signed an informed consent form. The
patients did not receive any financial reward or compensa-
tion for participating in this study. The study used a cross-
sectional design and was conducted at the public inpatient
care center of the Alcohol and Drugs Research Unit of the
Federal University of Sa˜o Paulo, which specializes in the
treatment of disorders related to substance use, is dedicated
exclusively to women, and is located within a tertiary
psychiatric hospital near Sao Paulo, Brazil. This unit has 28
beds for women over the age of 18 years, with an average
occupancy of 15 beds per month. The average duration of
treatment for each patient is approximately 45 days and
includes individual and group activities with a multi-
disciplinary staff that employs a combination of pharmaco-
logical treatment and several psychosocial approaches, such
as relapse prevention, 12-step program facilitation, motiva-
tional interviewing, cognitive behavioral therapy, harm
reduction, and complementary therapies, such as physical
activity and dance (18).
Procedures
During the eight months of data collection between
February 2011 and October 2011, a psychologist and a
nurse, both with expertise in addiction and previous
training, administered a questionnaire developed by the
authors to 105 women who had been diagnosed with
substance-related disorder and who were older than 18
years of age. All of the patients had a confirmed clinical
diagnosis of dependence according to the diagnosis criteria
of the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision, (19) up to the first
week of admission to this setting. The interview duration
was 40 minutes on average. No refusals were recorded.
Main outcomes measures
Socio-demographic data: The following socio-demo-
graphic data were collected: age, sexual orientation, educa-
tional level, ethnicity, marital status, monthly income,
employment status, and religious affiliation.
Drug of choice: The term "drug of choice" refers to the
preferred drug of the substance abuser, and this information
is often important to the clinical status of the patient because
substance users often meet diagnostic criteria for depen-
dence on multiple drugs. Certain characteristics, such as
age, race, and marital status, have been shown to vary
between individuals according to their drug of choice
preferences. These data are not collected on a scale, but
each patient is asked a simple question: ‘‘What is your drug
of choice?’’ (20).
Short Alcohol Dependence Data (SADD) questionnaire:
This instrument is a 15-item self-report questionnaire used
to provide a measure of the severity of alcohol dependence
within a continuum ranging from a mild drinking problem
to severe alcohol dependence; it evaluates the behavioral
and subjective aspects of alcohol dependence, with an
adequate construct validity and high correlation with other
instruments. The Brazilian version of the SADD and original
English version were highly correlated. The coefficient of
internal consistency was 0.79 (21).
Drug Abuse Screening Test (DAST-20): This survey
comprises 20 questions relating to drug use during the last
year. The questions pertain specifically to abuse, dependence,
withdrawal (signs and symptoms), social impairment, famil-
ial relationships, legal implications, medical problems, and
previous treatment. The problem severity was classified on a
scale from 0 to 20 and scored as follows: 0 = no problem; from
1 to 5 = mild; 6 to 10 = moderate; 11 to 15 = substantial; and 16
to 20 = severe. This scale has been used in several studies and
validated in other countries with good results in concurrent
and discriminate validity, but it has yet to be validated in
Brazil (22). Fagerstro¨m Test for Nicotine Dependence (FTND):
This questionnaire is a screening instrument that has been
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extensively translated and used in many countries, including
Brazil, to assess physical nicotine dependence. The instru-
ment consists of six items that are easily understood and can
be rapidly applied. The scores obtained on the test permit the
classification of nicotine dependence into five levels: very low
(0 to 2 points); low (3 to 4 points); moderate (5 points); high (6
to 7 points); and very high (8 to 10 points). The reliability
index of this instrument is excellent (0.87), and Cronbach’s
alpha coefficient ranged from 0.55 to 0.74, indicating that the
FTND has moderate internal consistency. The FTND showed
satisfactory sensitivity (0.75) and specificity (0.80) (23).
Arizona Sexual Experience Scale (ASEX): This instrument
is a scale designed to measure five specific items as the core
elements of sexual function: sexual drive, arousal, penile
erection/vaginal lubrication, ability to reach orgasm, and
satisfaction from orgasm. The instrument measures these
items with five questions in a relatively nonintrusive
bimodal fashion using a six-point Likert scale that ranges
from hyperfunction (1) to hypofunction (6). The scores
range from 5 to 30, and scores higher than or equal to 19
indicate sexual dysfunction. The ASEX was designed to be
either self- or clinically administered and can be used in
either heterosexual or homosexual populations, regardless
of whether the subject has a sexual partner. Questions
addressing the frequency/preference of sexual activity were
considered unrelated to sexual dysfunction. Cronbach’s
alpha analysis indicated that the ASEX demonstrated
excellent internal consistency and scale reliability
(alpha = 0.9055). The ASEX also demonstrated strong test-
retest reliability (for patients, r= 0.801, p,0.01; for controls,
r= 0.892, p,0.01). The sensitivity and specificity of the ASEX
in terms of the identification of sexual dysfunction were
82% and 90%, respectively (24). The main rationale for using
the ASEX scale instead of well-established measures for
sexual dysfunction in women, such as the Female Sexual
Function Index or Female Sexual Distress Scale, was that the
ASEX scale is shorter than those mentioned and more easily
incorporated into the protocols of our service, which already
includes many other instruments and also provides inpa-
tient care for men with substance-related disorders (6,7,18).
Data analyses
For the descriptive analysis, we evaluated the absolute
and relative frequencies of the categorical variables and
summary measures: means, quartiles, minimums, maxi-
mums and standard deviations of the numeric variables. To
investigate the association between the characteristics of the
categorical variables of the sample with sexual dysfunction
symptoms, we used the x2 test or Fisher exact test if the
sample was insufficient (25).
The use of categorical variables in the SADD, DAST-20,
FTND, and ASEX scales was adopted owing to their
nonlinear functional relationship with the variable of
interest and because the cut-off points are already well
accepted in the literature (18,25).
To compare the means of the numerical variables between
the two groups, we used the Student t test for independent
samples. To make comparisons between the averages of
more than two groups, we used an analysis of variance
(ANOVA) after confirming the assumption of observed data
normality using the Kolmogorov-Smirnov test (25).
Initially, all of the variables were included in the model.
Then, the variables that were not significant at the 5% level
were excluded one by one in order of significance (reverse
method). Furthermore, the Hosmer-Lemeshow test was
used to evaluate the suitability of model adjustment means
in the final model. The sensitivity and specificity were
calculated from the odds of sexual dysfunction final model,
which was estimated using the ROC curve (25).
In this study, two pseudo R2 (coefficient of determination)
values were obtained. The first was Cox-Snell, and the
second was Nagelkerke. Logistic regression does not have
an R2 value that allows a linear regression to explain the
variation of the model. Therefore, an attempt must be made
to obtain a statistically similar value; various pseudo R2
values have been proposed. It is important to note that the
R2 assumes nonnegative values (greater than or equal to
zero) but never reaches a value of one (in a linear regression,
the R2 takes values between zero and one, and one indicates
a perfect fit of the model). Therefore, because the pseudo R2
shares the same interpretation as the R2 (part of the
variability of the dependent variable 2 the outcome
explained by the regressors 2 explanatory variables), its
value must be assessed with caution (25).
Finally, for the joint assessment of the effects of
characteristics on sexual dysfunction symptoms, logistic
regression was used. For all of the statistical tests, a
significance level of 5% was used (25).
& RESULTS
Socio-demographic data
The sample consisted of 105 women, with a mean age of
34.8 years (SD = 12.1), an age range of 18-65 years (t= -1.41,
p= 0.16) and a median age of 31 years (second quartile). The
women were predominantly heterosexual (74.3%, n = 78),
single (47.6%, n = 50), Caucasian (50.5%, n = 53), and catholic
(36.2%, n = 38). They also had a monthly income of up to one
minimum wage, and 37.5% (n = 39) had an elementary
education, which equates to an average of approximately six
to seven years of study.
According to Table 1, the only association observed was
between education and sexual dysfunction symptoms 61.1%
(n = 22) of the women with sexual dysfunction symptoms
had not completed elementary school, whereas 29% (n = 20)
of the women with no sexual dysfunction symptoms had
not completed elementary school.
The average age of the women with sexual dysfunction
symptoms (n = 36) was 37.1 years (SD = 12.0), and the
average age of those without sexual dysfunction symptoms
(n = 69) was 33.6 years (SD = 12.1). There were no detectable
differences between the mean ages for sexual dysfunction
symptoms (t= -1.41, p= 0.16).
Prevalence of sexual dysfunction symptoms
In this sample, the prevalence of sexual dysfunction
symptoms was 34.2% (95% CI = [25.3, 44.1]) according to the
ASEX.
Affective sex orientation
The subjects were predominantly heterosexual (74.3%,
n = 78), followed by bisexual (17.1%, n = 18), and homo-
sexual (8.6%, n = 9). The proportion of exclusively homo-
sexual women was too small in our sample to conduct
any meaningful comparative analysis in terms of the preva-
lence of FSD symptoms in homosexual versus heterosexual
women.
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Characteristics related to substance abuse/
dependence
In 42.9% (n = 45) of the subjects, crack was the drug of
choice, followed by alcohol in 30% (n = 32) of subjects. In
addition, 47.6% of this sample presents a substantial level of
problems related to drugs according to the DAST-20; 43.8%
(n = 46) have a moderate or severe dependence on alcohol
according to SADD, and 47.6% (n = 60) have a high or very
high level of nicotine dependence according to FTND
(Table 2). There were no differences in the mean levels
between the ASEX, SADD (p= 0.50), DAST-20 (p= 0.67), and
FTND (p= 0.27).
Risk factors
Table 3 presents the final logistic regression model. The
coefficients associated with the incomplete high school and
high school levels of education were similar (p= 0.78);
therefore, these two categories were combined to increase
the regression model degrees of freedom due to sample
size. The same occurred with the levels of DAST-20; the
Table 1 - Sociodemographic data and sexual dysfunction symptoms (N=105).
Total Sexual Dysfunction Symptoms OR 95% CI for OR
Negative Positive
N % N % N %
Affective sex orientation 105 100.0% 69 100.0% 36 100.0%
Heterosexual 78 74.3% 49 71.0% 29 80.6% 1.0 -
Homosexual 9 8.6% 7 10.1% 2 5.6% 0.48 [0.09; 2.52]
Bisexual 18 17.1% 13 18.8% 5 13.9% 0.65 [0.21; 2.03]
x2 = 1.21 (p=0.5462)
Marital status 105 100.0% 69 100.0% 36 100.0%
Single 50 47.6% 33 47.8% 17 47.2% 1.0 -
Separated/Divorced 20 19.0% 13 18.8% 7 19.4% 1.05 [0.35; 3.13]
Married 16 15.2% 10 14.5% 6 16.7% 1.16 [0.36; 3.79]
Stable union 13 12.4% 10 14.5% 3 8.3% 0.58 [0.14; 2.44]
Widow 6 5.7% 3 4.3% 3 8.3% 1.94 [0.34; 10.93]
Fisher test (p=0.8444)
Schooling 105 100.0% 69 100.0% 36 100.0%
Illiterate 2 1.9% 0 0.0% 2 5.6%
Elementary school 42 40.0% 20 29.0% 22 61.1% 1.0 -
Complete basic education 3 2.9% 2 2.9% 1 2.8% 0.45 [0.04; 5.62]
Incomplete secondary education 13 12.4% 11 15.9% 2 5.6% 0.17 [0.03; 0.93]
Complete secondary education 31 29.5% 27 39.1% 4 11.1% 0.13 [0.04; 0.51]
Incomplete higher education 11 10.5% 7 10.1% 4 11.1% 0.52 [0.13; 2.10]
Complete higher education 3 2.9% 2 2.9% 1 2.8% 0.45 [0.04; 5.62]
Fisher test (p=0.0011)
Race 105 100.0% 69 100.0% 36 100.0%
Caucasian 53 50.5% 36 52.2% 17 47.2% 1.0 -
Latino descendants 37 35.2% 25 36.2% 12 33.3% 1.02 [0.41; 2.51]
Indigenous descents 3 2.9% 1 1.4% 2 5.6% 4.24 [0.34; 52.93]
Asian descendants 1 1.0% 1 1.4% 0 0.0% 0.00 -
African descendants 11 10.5% 6 8.7% 5 13.9% 1.76 [0.46; 6.72]
Fisher test (p=0.6401)
Religion 105 100.0% 69 100.0% 36 100.0%
Catholic 38 36.2% 25 36.2% 13 36.1% 1.0 -
Evangelical 33 31.4% 22 31.9% 11 30.6% 0.96 [0.36; 2.60]
No religion 19 18.1% 11 15.9% 8 22.2% 1.40 [0.45; 4.39]
African religion 5 4.8% 5 7.2% 0 0.0% 0.0 -
Others (e.g., buddhism) 2 1.9% 1 1.4% 1 2.8% 1.92 [0.11; 34.80]
Spiritualist 6 5.7% 3 4.3% 3 8.3% 1.92 [0.33; 11.25]
Atheist 2 1.9% 2 2.9% 0 0.0% 0.0 -
Fisher test (p=0.5676)
Employment 105 100.0% 69 100.0% 36 100.0%
Unemployed 60 57.1% 40 58.0% 20 55.6% 1.0 -
Informal job 19 18.1% 14 20.3% 5 13.9% 0.71 [0.22; 2.29]
Formal job 10 9.5% 7 10.1% 3 8.3% 0.86 [0.20; 3.71]
Social security benefits 8 7.6% 3 4.3% 5 13.9% 3.33 [0.69; 16.02]
Retired 7 6.7% 4 5.8% 3 8.3% 1.5 [0.30; 7.47]
Student 1 1.0% 1 1.4% 0 0.0% 0.00 -
Fisher test (p=0.5355) 0.0
Salary range 104 100.0% 69 100.0% 35 100.0%
Without income 10 9.6% 6 8.7% 4 11.4% 3.0 [0.37; 24.45]
Up to 1 SW 39 37.5% 21 30.4% 18 51.4% 3.86 [0.69; 21.59]
1 to 3 SW 31 29.8% 24 34.8% 7 20.0% 1.31 [0.22; 7.72]
3 to 5 SW 13 12.5% 9 13.0% 4 11.4% 2.0 [0.27; 14.71]
Above 5 SW 11 10.6% 9 13.0% 2 5.7% 1.0 -
Fisher test (p=0.2228)
CI =Confidence interval; OR=Odds ratio. Footnote: SW=minimum wage. In Brazil 1 SW=R$ 622/US$330.
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coefficients associated with the low, moderate, substantial
and severe levels were similar (p= 0.71).
The variable salary and DAST-20, although not significant
at the 5% level, were maintained in the sample because they
were marginally significant. It can be observed in this table
that women who have had secondary education (complete
or incomplete) have an 80% reduced chance of presenting
dysfunction symptoms compared with women with lower
levels of education.
However, women with a high level of nicotine depen-
dence increased their chance of presenting sexual dysfunc-
tion symptoms by 2.72 compared with women of other
levels of drug dependence. The Hosmer-Lemeshow test
(p= 0.48) indicated a good adequacy of fit to the model.
From the final model, it is possible to use the characteristics
of women in terms of education, FTND, DAST-20, and
salary to estimate the probability of having FSD symptoms.
Using the ROC curve, we obtained a cut-off of 0.31 in
probability, which was associated with a sensitivity of 82.9%
and specificity of 68.1%. Hence, if all of the women with a
probability greater than 0.31 are classified as having sexual
dysfunction symptoms, the model classifies 82.9% of
women who truly have positive sexual dysfunction symp-
toms. In addition, among the women who do not have
Table 2 - Dependence level and sexual dysfunction symptoms (N=105)
Total Sexual Dysfunction Symptoms ODD RATIO 95% CI for OR
Negative Positive
N % N % N %
SADD 105 100.0% 69 100.0% 36 100.0%
Mild dependence 35 33.3 27 39.1% 8 22.2% 1.00 -
Moderate dependence 21 20.0% 11 15.9% 10 27.8% 3.07 [0.91 ; 10.35]
Serious dependence 25 23.8% 14 20.3% 11 30.6% 2.65 [0.84 ; 8.42]
No alcohol abuse/use 24 22.9% 17 24.6% 7 19.4% 1.39 [0.42 ; 4.59]
x2=5,01 (p=0.1709)
DAST20 105 100.0% 69 100.0% 36 100.0%
No problem 10 9.5% 4 5.8% 6 16.7% 1.0 -
Low level 4 3.8% 2 2.9% 2 5.6% 0.67 [0.06 ; 7.58]
Moderate level 17 16.2% 11 15.9% 6 16.7% 0.36 [0.07 ; 1.97]
Substantial level 50 47.6% 36 52.2% 14 38.9% 0.26 [0.06 ; 1.12]
Severe level 11 10.5% 9 13.0% 2 5.6% 0.15 [0.02 ; 1.41]
No drug abuse/use 13 12.4% 7 10.1% 6 16.7% 0.57 [0.10 ; 3.20]
Fisher test (p=0.2604)
DOC 105 100.0% 36 100.0% 69 100.0%
Crack 45 42.9% 11 30.6% 34 49.3% 1.0 -
Cocaine 25 23.8% 9 25.0% 16 23.2% 1.74 [0.59 ; 5.11]
Marijuana 2 1.9% 1 2.8% 1 1.4% 3.09 [0.17 ; 56.47]
Opioid 1 1.0% 0 0.0% 1 1.4% - -
Alcohol 32 30.5% 15 41.7% 17 24.6% 2.73 [1.00 ; 7.46]
Fisher test (p=0.2222)
FARGESTRON 105 100.0% 69 100.0% 36 100.0%
Very low 27 25.7% 20 28.9% 7 19.4% 1.0 -
Low 9 8.6% 8 11.6% 1 2.8% 0.36 [0.04 ; 3.60]
Average 11 10.5% 7 10.1% 4 11.1% 1.63 [0.35 ; 7.53]
Elevate 33 31.4% 17 24.6% 16 44.4% 2.69 [0.86 ; 8.40]
Very elevate 17 16.2% 12 17.4% 5 13.9% 1.19 [0.30; 4.68]
No smoking 8 7.6% 5 7.2% 3 8.3% 1.71 [0.31 ; 9.43]
Fisher test (p=0.3115)
CI = Confidence interval; OR= Odds ratio.
Table 3 - Risk factors associated with female sexual dysfunction.
Standard Error Odds ratio IC95% p-value
Schooling
High school incomplete/complete 0.54 0.20 [0.07; 0.56] 0.0025
Other levels of education - 1.00 -
Salary range
Up to 1 SW 0.48 2.54 [0.99; 6.52] 0.0519
Others - 1.00 -
Fagerstro¨m
Elevate 0.50 2.72 [1.02; 7.28] 0.0455
Others - 1.00 -
DAST20
No drug dependence - 1.00 -
Others levels 0.55 0.36 [0.12; 1.06] 0.0644
Constant 0.51 0.91 0.8483
IC 95% - Confidence interval 95%. SW: minimum wage.
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sexual dysfunction symptoms, 68.1% are properly classified
as not having sexual dysfunction symptoms. In this study,
two pseudo R2 were obtained. The first was Cox-Snell and
had a value of 0.21, and the second was Nagelkerke and had
a value of 0.29.
& DISCUSSION
Socio-demographic factors, such as age, marital status,
income, and education, have been strongly predictive of
sexual dysfunction symptoms in women (3,4). In this
sample, a significant association between sexual dysfunc-
tion symptoms and socio-demographic characteristics was
observed only for schooling, which is in agreement with
other international studies showing that levels of sexual
dysfunction are higher in women with low levels of
education (3,4).
In addition to education, another finding that stands out
and concurs with other international studies refers to the
2.54 fold increased chance of sexual dysfunction symptoms
in women with low income. Women who subsist on a low
income comprise a high-risk vulnerable population with
limited access to social and health services. In general, this
population is also more vulnerable to poverty and higher
levels of sexual crime and violence than most other
populations investigated in sexual function studies (3). For
women addicted to alcohol and drugs, these vulnerabilities
may be heightened because the consumption of drugs,
especially crack, has been associated with various types of
violence and the exchange of sex for drugs in women (18).
The prevalence of 34.2% FSD symptoms in this sample of
women with substance-related disorder was common and
comparable to other studies reported worldwide, which
have reported prevalence rates of FSD symptoms of 12-63%
(3,6,10), even in a sample of women with severe psychoac-
tive substance dependence, as determined by the DAST-20,
SADD, and FTND scales. Consequently, we expected to find
higher sexual dysfunction symptom prevalence rates than
in the general population.
Another finding that is in accordance with the current
scientific evidence is the association between severe nicotine
dependence and sexual dysfunction symptoms, which was
almost threefold the odds ratio compared with women of
other nicotine dependence levels in our sample (10).
Scientific evidence has suggested that long-term cigarette
smoking is an independent risk factor for sexual dysfunc-
tion in men (26,27). However, the results of the limited data
investigating this relationship in women are diverse, and
some of the evidence supports the suggestion that nicotine
may be the primary pharmacological agent responsible for
genital hemodynamic disturbance, thereby facilitating a
cascade of vascular and biochemical events that may
obstruct normal sexual arousal responses in women.
Controlled experimental studies examining the acute and
chronic effects of isolated nicotine intake on female
physiological sexual responses are necessary to help clarify
the potential role of tobacco in the development and/or
maintenance of sexual dysfunction in women (26,27).
Although FSD has been investigated in groups of women
with various health problems, such as polycystic ovary
syndrome, diabetes, HIV, and breast cancer (28-30), women
with substance-related disorder represent a unique under-
served and vulnerable population that continues to suffer
from low detection rates and limited access to treatment
(18).
The strong point of this study is on the recruitment of this
special group of women because little focus has been given
to the link between these two issues—sexual dysfunction
symptoms and alcohol and drug dependence—using
validated questionnaires as the assessment measures,
especially in Brazil and other Latin American countries,
where very few studies have been conducted on this
association at alcohol and drug dependence services (31).
This study is limited by its cross-sectional design and the
relatively small sample size. Only associations, not causal
relationships, can be inferred from cross-sectional studies. A
longitudinal study design would allow causality related to
the onset of substance use and reported sexual dysfunction
symptoms. Beyond that issue, because the recruitment took
place at a tertiary service, this sample of women may not be
representative of the community because it can be assumed
that only the most serious patients receive this type of
treatment (18). This sample bias may therefore limit the
external validity of these findings.
Another limitation is that psychiatric comorbidities, detox
periods, the use of medication, and other medical conditions
that might cause sexual dysfunction symptoms were not
investigated or controlled; therefore, they might be potential
confounding factors (3-5).
Another limitation that should be noted is that the
authors have chosen not to examine the individual sexual
functions affected and the various explanatory variables, as
there are known differences in the etiology of various
symptoms of sexual dysfunction, such as those affecting the
phases of desire and arousal (3,7). However, future studies
may focus on this topic, expanding the scientific evidence
on this theme.
The clinical implications of the findings of this study
indicate that addressing sexual dysfunction should be part
of the recovery process of the recovering addict and should
not be marginalized or made invisible in most rehabilitation
centers (32). When sexual health and sexual dysfunction are
not directly addressed in alcohol and drug treatment
centers, they may contribute to treatment failure with
relapses and consequently, substantial losses in the life
quality of the addict (32). Many patients come to treatment
with feelings of guilt and shame related to their sexual
behavior when using, which can contribute to relapse and
noncompliance if the issue is not addressed (32).
For example, alcohol-dependent women with vaginismus
can relapse and use alcohol to cope with their sexual
dysfunction, as may other women who use alcohol to
achieve sexual excitement or relaxation during sex (32).
Therefore, recovery offers an excellent opportunity to
identify, prevent, and manage sexual dysfunction symp-
toms in women with problems related to alcohol and other
drugs (31,32).
Future substance abuse population-based and longitudi-
nal studies should be conducted to extend the scientific
evidence, including the research on sexual dysfunction and
sexual health. It is especially important to study crack
smokers because this drug has become a public health
problem in many low to middle income countries (33).
In conclusion, FSD symptoms in this sample were
common and primarily associated with high levels of
nicotine dependence.
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